An Open-label, Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pirarubicin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide phosphate; Ifosfamide; Methotrexate; Prednisone; Vincristine
Indications T-cell lymphoma
Focus Therapeutic Use

06 Nov 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified November 2017).
10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
10 Nov 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com